We are excited to announce that the Center for RNA Biomedicine has now entered into Phase II of its mission.  

To fully unlock the potential of RNA therapeutics, we are actively fundraising for the new Nucleic Acid Synthesis Core. This Nucleic Acid Therapeutics (NATx) initiative aims to provide high-quality, cost-effective enzymatically and chemically synthesized RNAs for preclinical research accessible to researchers and clinicians at the University of Michigan and beyond. Free from commercial constraints, this resource will further accelerate breakthroughs in personalized RNA medicines, positioning the U-M as a “leaders and best” community at the forefront of innovation, both nationally and globally.